Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eojXCfbwocfFobcZrzQi

March 25, 2013
Are you part of a BD or licensing team and want to improve your skills in contracts, intellectual property, valuation and deal structuring? Register for BIO's Executive Training Courses, April 19-21, in Chicago.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • Report: 465 chronic-disease drugs are under development
    The U.S. biopharmaceutical industry is developing 465 new drugs that target the top 10 chronic diseases affecting individuals 65 and older, according to a Pharmaceutical Research and Manufacturers of America report. The lineup includes 40 for chronic obstructive pulmonary disease, 48 for heart failure, 82 for Alzheimer's, 92 for osteoarthritis and rheumatoid arthritis, and 142 for diabetes. Other treatments under development target osteoporosis, cataracts, depression and chronic kidney disease. PharmaTimes (U.K.) (3/22) LinkedInFacebookTwitterEmail this Story
The New You Starts Here.
Designed for busy healthcare professionals, FIU's online Healthcare MBA is transformative. Graduates emerge ready for a leadership role in healthcare, with a clear vision of how to lead collaboratively and advance the business of healthcare. Classes begin Fall 2015. Start here.

  Health Care & Policy 
 
  • J&J threatens to put a wrinkle in Botox's dominance
    Johnson & Johnson expects to receive FDA approval next year for a wrinkle-reducing injection similar to Allergan's Botox. Allergan already faces competition from Valeant's Dysport and Merz's Xeomin, but it has an 85% market share. Reuters (3/22) LinkedInFacebookTwitterEmail this Story
  • Alimera again submits DME drug Iluvien for U.S. approval
    Alimera Sciences plans to resubmit Iluvien, a drug candidate for chronic diabetic macular edema, for FDA approval by the end of this month. Alimera licensed the drug from pSivida. The application will highlight the drug's safety profile and will focus on chronic DME patients who don't respond satisfactorily to existing treatments. The drug has been approved in the U.K., Germany, France and several other European countries. In 2011, the FDA requested additional trials. ProactiveInvestors.co.au (Australia) (3/25), Australian Life Scientist (3/25) LinkedInFacebookTwitterEmail this Story
Don't lose access to your customer's facility. We can help.
Rep-Clear: Watermark's Solution for ensuring access to your customers. Rep-Clear includes our proprietary platform for tracking all items associated with a Rep and our professional support staff to provide individual service, ensuring all items are up to date and access to a facility is not lost. View common rep excuses.

  Company & Financial News 
Is Pricing Low Your Strategy to Success? Think again.
Pricing is the heart of a business. It affects everything you do and is affected by everything you do. Economists talk of supply and demand as key factors behind pricing—successful entrepreneurs manipulate demand by making their products more desirable. These six steps will help you determine the right price for your product or service, read the article and learn how to get pricing right.

  Food & Agriculture 
 
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Report: 10 cellulosic fuel plants could go online through 2014
    At least 10 commercial-scale cellulosic biofuel plants are expected to go online through next year, according to a report from a pair of researchers at the Bioeconomy Institute at Iowa State University. The projects include a Sundrop Fuels facility in Alexandria, La., and a KiOR project in Natchez, Miss. BiofuelsDigest.com (3/22) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
A thing is mighty big when time and distance cannot shrink it."
--Zora Neale Hurston,
American author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information